Press coverage about Global Blood Therapeutics (NASDAQ:GBT) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Global Blood Therapeutics earned a news impact score of 0.12 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.2012670788569 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Cowen Reaffirms “Buy” Rating for Global Blood Therapeutics (GBT) (americanbankingnews.com)
- Hilly Stocks: Twenty-First Century Fox, Inc. (NASDAQ:FOX), Sibanye Gold Limited (NYSE:SBGL), Global Blood … (journalfinance.net)
- Zacks: Brokerages Expect Global Blood Therapeutics Inc (GBT) Will Post Earnings of -$0.85 Per Share (americanbankingnews.com)
- Global Blood Therapeutics’ (GBT) “Buy” Rating Reaffirmed at Cantor Fitzgerald (americanbankingnews.com)
- Global Blood Therapeutics (GBT) Given a $125.00 Price Target by HC Wainwright Analysts (americanbankingnews.com)
Shares of GBT stock opened at $45.15 on Tuesday. Global Blood Therapeutics has a twelve month low of $26.10 and a twelve month high of $68.05. The company has a market capitalization of $2.40 billion, a price-to-earnings ratio of -16.36 and a beta of 4.21.
A number of research analysts recently issued reports on the company. Needham & Company LLC restated a “buy” rating and set a $70.00 price target on shares of Global Blood Therapeutics in a research note on Thursday, April 26th. Zacks Investment Research upgraded Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Oppenheimer dropped their price target on Global Blood Therapeutics from $79.00 to $74.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 8th. SunTrust Banks dropped their price target on Global Blood Therapeutics from $80.00 to $77.00 and set a “buy” rating on the stock in a research note on Tuesday, May 8th. Finally, ValuEngine upgraded Global Blood Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 8th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $80.53.
In other news, insider Lesley Ann Calhoun sold 3,295 shares of the firm’s stock in a transaction that occurred on Monday, July 9th. The stock was sold at an average price of $44.19, for a total value of $145,606.05. Following the completion of the sale, the insider now directly owns 1,388 shares of the company’s stock, valued at approximately $61,335.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jung Choi sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 17th. The shares were sold at an average price of $48.25, for a total value of $144,750.00. Following the completion of the sale, the insider now directly owns 136,077 shares of the company’s stock, valued at $6,565,715.25. The disclosure for this sale can be found here. Insiders sold a total of 49,674 shares of company stock valued at $2,173,615 over the last three months. Insiders own 4.40% of the company’s stock.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J.
Read More: Investing in Growth Stocks
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.